TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...

Jabil signs Memoranda of Understanding (MoUs) with Gujarat and Tamil Nadu states to explore expansion opportunities.,Focus on ...

FOSTER CITY, Calif., November 14, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company ...

Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 ...

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

There were some impressive earnings movers last week lead by Applovin’s (APP) 46% rally. CVS Corp (CVS), Palantir (PLTR) and Gilead Sciences (GILD) also had big rallies, while Super Micro Computer’s ...